Drug development

Immunity
#Cancer research #Cancer vaccines #Drug development #Drug discovery #Immuno-oncology #Sino Biological

Register now: Advances driving immuno-oncology drug discovery

This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. It will take place on Wednesday, October 21, 2026 at 7am PDT / 10am EDT / 3pm BST / 4pm CEST. Featuring expert presentations and a panel… Read More

#News

#Biopharma #Drug development #Drug discovery #Women in STEM

Women in biopharma: Charlotte Edenius, Gesynta 

In this series, DDW speaks to women in leading positions across biopharma about the work they’re doing and their experiences within the industry. Here, we speak to Charlotte Edenius, Gesynta, co-founder and VP of R&D Strategy of Gesynta Pharma about the company's approach to treating pain and inflammation and her… Read More

#Exclusive Content

#Drug development #Drug discovery #Interview #ProBio #Sitting Down With #Vodcast

New vodcast: Sitting Down With… Derek Chen, ProBio

The latest episode of the DDW Sitting Down With vodcast is sponsored by ProBio, and our guest is Derek Chen, who Multimedia Editor Megan Thomas interviewed on how AI is transforming antibody drug discovery, from identifying and prioritising candidates to early developability assessment, experimental validation and the integration of discovery,… Read More

#News

#Drug development #Drug discovery #Interview #ProBio #Sitting Down With #Vodcast

Vodcast: Sitting Down With… Derek Chen, ProBio

The latest episode of the DDW Sitting Down With vodcast is sponsored by ProBio, and our guest is Derek Chen, who Multimedia Editor Megan Thomas interviewed on how AI is transforming antibody drug discovery, from identifying and prioritising candidates to early developability assessment, experimental validation and the integration of discovery,… Read More

#Videos

#Drug activity #Drug development #Drug discovery #GPCR

Register now: Revealing hidden pharmacology with GPCR assays

The pharmacological behaviour of drugs is determined not only by their intrinsic properties but also by the sensitivity of the biological systems in which they are evaluated. Variations in receptor density and signal transduction efficiency can significantly influence observed drug responses, complicating the translation of in vitro findings to in… Read More

#News

#Drug activity #Drug development #Drug discovery #GPCR

Improving the predictive power of GPCR assays: Revealing hidden pharmacology

The pharmacological behaviour of drugs is determined not only by their intrinsic properties but also by the sensitivity of the biological systems in which they are evaluated. Variations in receptor density and signal transduction efficiency can significantly influence observed drug responses, complicating the translation of in vitro findings to in… Read More

Webinar date:
Supported by Eurofins DiscoverX
#Webinars

#Cancer research #Cancer vaccines #Drug development #Drug discovery #Immuno-oncology #Sino Biological

Summit: Advances driving immuno-oncology drug discovery

This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. Featuring expert presentations and a panel discussion, the summit will explore topics such as how to tackle cancer drug resistance, personalised medicine, cytotoxic therapy in the immunotherapy… Read More

#News

#Cancer research #Cancer vaccines #Drug development #Drug discovery #Immuno-oncology #Sino Biological

The advances driving immuno-oncology drug discovery

This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. Featuring expert presentations and a panel discussion, the summit will explore topics such as how to tackle cancer drug resistance, personalised medicine, cytotoxic therapy in the immunotherapy… Read More

Webinar date:
Sponsored by Sino Biological
#Webinars

Molecular,Model,Of,Antibody
#Antibody engineering #Automation / robotics #Drug development #Generative AI

Antibody engineering after generative AI: Solving the validation bottleneck

Stacey Willard, Vice President of Marketing and Product Management at Nuclera, explores the validation bottleneck for antibody engineering and why generative AI may be the answer to this challenge.  Antibody engineering has developed a pronounced asymmetry. AI can now generate and rank antibody candidates at a pace that conventional experimental… Read More

#Exclusive Content

#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

Last chance to register: Drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More

#News

#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

Webinar explores drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More

#News

Cancer cells
#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

Drug discovery challenges in cancer research webinar

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at… Read More

#News

#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

Register to learn about the drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More

#News

Cancer cells
#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More

#News

Cancer cells
#BioIVT #Cancer research #Drug development #Drug discovery #iOnctura #Kazia Therapeutics #Sartorius #Vyriad Therapeutics #Webinar

Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development. You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics… Read More

Webinar date:
Co-sponsored by BioIVT and Sartorius
#Webinars

Tumour microenvironment
#Akiram Therapeutics #Cancer research #Drug development #Radionuclide therapy #Radiopharmaceuticals #Solid tumours

Partnership supports radiopharmaceutical solid tumour development

Akiram Therapeutics has signed an agreement with ITM for the supply of non-carrier-added lutetium-177 (n.c.a. Lu-177) to support the ongoing clinical trial of AKIR001, its lead radiopharmaceutical candidate for the treatment of solid tumours. Lu-177 is one of the most widely used medical radioisotopes in targeted radionuclide therapy and serves… Read More

#News